
Claims:

1. Use of AZD5305 in the manufacture of a medicament for ~~A method of~~ treating cancer in a human subject in need thereof, ~~comprising administering to the human subject~~wherein AZD5305 is:



;

wherein a first amount of AZD5305 or a pharmaceutically acceptable salt thereof, and a second amount of a platinum chemotherapeutic agent or a pharmaceutically acceptable salt thereof are to be administered to the human subject; wherein the first amount and the second amount together comprise a therapeutically effective amount.

2. The ~~method~~ use according to claim 1, wherein the cancer is selected from ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, hematological cancer, gastrointestinal cancer such as gastric cancer and colorectal cancer, and lung cancer.

3. The ~~method~~ use according to claim 1 or claim 2, wherein the platinum chemotherapeutic agent is selected from any one of cisplatin, oxaliplatin, and carboplatin.


4. The ~~method~~ use according to any one of claims 1 to 3, wherein the cancer is homologous recombination deficient (HRD) cancer.

5. The ~~method~~ use according to claim 4, wherein the cancer comprises one or more cells having a mutation in an HRR gene selected from *BRCA1*, *BRCA2*, *ATM*, *BRIP1*, *BARD1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *PPP2R2A*, *RAD51B*, *RAD51C*, *RAD51D*, and *RAD54L*.

6. The ~~method~~ use according to claim 5, wherein the mutated HRR gene is selected from *BRCA1*, *BRCA2*, and *ATM.*

7. A kit comprising:


a first pharmaceutical composition comprising AZD5305 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein AZD5305 is:



; and

a second pharmaceutical composition comprising a platinum chemotherapeutic agent or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, and instructions for use.

8. AZD5305, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a subject, wherein said treatment comprises the separate, sequential or simultaneous administration of i) said AZD5305, or a pharmaceutically acceptable salt thereof, and ii) a platinum chemotherapeutic agent, or a pharmaceutically acceptable salt thereof, to said subject, wherein AZD5305 is:



.

9. The compound according to claim 8, wherein the cancer is selected from ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, hematological cancer, gastrointestinal cancer such as gastric cancer and colorectal cancer, and lung cancer.


10. The compound according to claim 8 or claim 9, wherein the platinum chemotherapeutic agent is selected from any one of cisplatin, oxaliplatin, and carboplatin.

11. The compound according to any one of claims 8 to 10, wherein the cancer is homologous recombination deficient (HRD) cancer.

12. The compound according to claim 11, wherein the cancer comprises cells having a mutation in an HRR gene selected from *BRCA1*, *BRCA2*, *ATM*, *BRIP1*, *BARD1*, *CDK12*, *CHEK1*, *CHEK2*, *FANCL*, *PALB2*, *PPP2R2A*, *RAD51B*, *RAD51C*, *RAD51D*, and *RAD54L*.

13. The compound according to claim 12, wherein the mutated HRR gene is selected from *BRCA1*, *BRCA2*, and *ATM.*

14. A pharmaceutical product comprising i) AZD5305 or a pharmaceutically acceptable salt thereof, and ii) a platinum chemotherapeutic agent or a pharmaceutically acceptable salt thereof, wherein AZD5305 is:



.

15. The pharmaceutical product according to claim 14, wherein AZD5305 or a pharmaceutically acceptable salt thereof and the platinum chemotherapeutic agent or a pharmaceutically acceptable salt thereof are present in a single dosage form.

16. The pharmaceutical product according to claim 14, wherein AZD5305 or a pharmaceutically acceptable salt thereof and the platinum chemotherapeutic agent or a pharmaceutically acceptable salt thereof are present in separate dosage forms.

17. The ~~method~~use, compound or pharmaceutical composition according to any preceding claim wherein the platinum chemotherapeutic agent comprises carboplatin.

18. The ~~method~~use, compound or pharmaceutical composition according to any preceding claim wherein the platinum chemotherapeutic agent is carboplatin.

19. The ~~method~~use, compound or pharmaceutical composition according to any preceding claim wherein the AZD5305 is the free base.

20. The pharmaceutical product according to claim 14 for use in therapy.